Investor Presentation - drreddys.com
Key strengths and capabilities Industry leading product development skills Deep market presence Early mover advantage in Biosimilars Collaboration across business units
Download Investor Presentation - drreddys.com
Information
Domain:
Source:
Link to this page:
Documents from same domain
Press Release - drreddys.com
www.drreddys.comAn overdose and even death can happen if you take benzodiazepines, sedatives, tranquilizers, antidepressants, or alcohol while using Buprenorphine and …
Dr. Reddy’s
www.drreddys.comInvestor Presentation - 2015 Dr. Reddy’s Laboratories Ltd. 4 Contents 1. Update on US FDA matter 2. Executive Summary 3. Company Overview …
Press Release - Dr.Reddy's
www.drreddys.comEarnings Call Details (06:30 pm IST, 09:00 am EDT, October 31, 2017) The Company will host an earnings call to discuss the performance and answer any questions
“Dr. Reddy’s Laboratories Limited Q3 FY2018 …
www.drreddys.comPage 1 of 21 “Dr. Reddy’s Laboratories Limited Q3 FY2018 Earnings Conference Call” January 25, 2018
DR. REDDY’S LABORATORIES LIMITED
www.drreddys.comDR. REDDY’S LABORATORIES LIMITED | ANNUAL REPORT 2016-17 Accelerating Access to Good Health Dr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills,
DR. REDDY’S LABORATORIES LTD
www.drreddys.com3 Safe harbor statement DR. REDDY’S 2015 INVESTOR DAY This presentation contains forward-looking statements and information that …
SUMMARY OF PRODUCT CHARACTERISTICS - …
www.drreddys.comSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Amlodipine 10mg Tablets . 2. QUALITATIVE AND QUANTITATIVE COMPOSITION . Each tablet contains amlodipine maleate equivalent to …
DR. REDDY’S LABORATORIES LIMITED
www.drreddys.comDr. Reddy’s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034, India www.drreddys.com DR. REDDY’S LABORATORIES LIMITED | …
PRODUCT MONOGRAPH BORTEZOMIB FOR …
www.drreddys.com5 Tumour L ysis Syndrome: Because bortezomib for injection is a cytoto xic agent and can rapi dly kill m alignant plas m a cells, the co …
BRAND-TO-GENERIC- TO-BRAND - Dr.Reddy's
www.drreddys.com4 SEC 1 Good Health Can't Wait. Access to many of today’s expensive, life-changing medicines remains a hurdle for countless Americans. Helping overcome
Related documents
Trends & Opportunities for Indian Pharma
ficci.inForeword The Indian pharmaceutical industry has contributed significantly to global healthcare by ensuring high quality, affordable and accessible medicines around the world.
REPORT - Biologic Innovation, Quality & Reliability
www.amgenbiotech.com3. WHAT ARE BIOLOGICS AND BIOSIMILARS? A biologic medicine is a large molecule derived from living cells that is used to treat or prevent disease, such as a therapeutic protein, DNA vaccine, monoclonal antibody (i.e., MAB) or fusion
The U.S. Biosimilars Market
www.dean.com4 The U.S. Biosimilars Market Key Biologic Sales vs. Complexity U.S. Sales, 2008 Each of the factors outlined above will have wide-reaching implications for biosimilar developers, big pharma and
Dr. Reddy’s
www.drreddys.comInvestor Presentation - 2016 Dr. Reddy’s Laboratories Ltd. 6 Executive Summary • During the last decade, our top line grew at 18% CAGR with healthy profitability, on the back of strong performance from US generics and branded formulations in Emerging markets.